| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
The molecular targets include BCR-ABL1, where radotinib inhibits kinase activity and blocks proliferation of CML cells, and additional kinases such as DDR1, c-KIT, and PDGFR; in Parkinson’s disease models, radotinib activates the ubiquitin-proteasome system and reduces α-synuclein aggregation through a kinase-independent mechanism.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
In vitro, radotinib-d6 inhibits BCR-ABL1 kinase activity and suppresses proliferation of CML cell lines, and it reduces α-synuclein aggregation and activates proteasomal activity in neuronal cells; the deuterated form retains BCR-ABL1 inhibitory and neuroprotective activity while enabling LC-MS/MS quantification in plasma and tissue. |
| ln Vivo |
In vivo, oral radotinib-d6 suppresses BCR-ABL1–driven tumor growth in CML xenograft models and improves motor function and reduces α-synuclein pathology in Parkinson’s disease models; the labeled form is used to quantify plasma and brain concentrations and to relate kinase occupancy to antitumor and neuroprotective effects.
|
| Enzyme Assay |
Noncellular kinase assays incubate recombinant BCR-ABL1 or other kinases with a peptide substrate and [γ-32P]ATP or a fluorescent ATP analog and increasing concentrations of radotinib-d6; phosphorylation is quantified by scintillation counting or fluorescence polarization, and IC50 values are derived, with selectivity screened against a panel of kinases.
|
| Cell Assay |
Cellular assays use CML cell lines or neuronal cells treated with radotinib-d6; BCR-ABL1 autophosphorylation and downstream STAT5 phosphorylation are measured by immunoblotting, cell viability by CellTiter-Glo, and α-synuclein aggregation by thioflavin T fluorescence or immunoblotting, with proteasomal activity measured by fluorogenic substrate cleavage.
|
| Animal Protocol |
Animal protocols administer radotinib-d6 orally to mice bearing BCR-ABL1–driven tumors or to Parkinson’s disease models at doses of 10–100 mg/kg; tumor growth, motor function, and α-synuclein pathology are measured, and plasma and brain concentrations are quantified by LC-MS/MS to relate kinase occupancy to antitumor and neuroprotective efficacy.
|
| References |
|
| Molecular Formula |
C27H21F3N8O
|
|---|---|
| Molecular Weight |
536.540824651718
|
| Exact Mass |
536.216
|
| CAS # |
2754051-83-5
|
| Related CAS # |
Radotinib;926037-48-1
|
| PubChem CID |
163322424
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
3.9
|
| tPSA |
111
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
39
|
| Complexity |
818
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
FC(C1C=C(C=C(C=1)N1C=NC(C)=C1)NC(C1C([2H])=C([2H])C(C([2H])([2H])[2H])=C(C=1[2H])NC1N=CC=C(C2C=NC=CN=2)N=1)=O)(F)F
|
| InChi Key |
DUPWHXBITIZIKZ-LJVZJTOJSA-N
|
| InChi Code |
InChI=1S/C27H21F3N8O/c1-16-3-4-18(9-23(16)37-26-33-6-5-22(36-26)24-13-31-7-8-32-24)25(39)35-20-10-19(27(28,29)30)11-21(12-20)38-14-17(2)34-15-38/h3-15H,1-2H3,(H,35,39)(H,33,36,37)/i1D3,3D,4D,9D
|
| Chemical Name |
2,3,6-trideuterio-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-5-[(4-pyrazin-2-ylpyrimidin-2-yl)amino]-4-(trideuteriomethyl)benzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8638 mL | 9.3190 mL | 18.6379 mL | |
| 5 mM | 0.3728 mL | 1.8638 mL | 3.7276 mL | |
| 10 mM | 0.1864 mL | 0.9319 mL | 1.8638 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.